Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance.
about
Trial Watch: Adoptive cell transfer for oncological indicationsTreg functional stability and its responsiveness to the microenvironmentPoly(I:C) and Lipopolysaccharide Innate Sensing Functions of Circulating Human Myeloid Dendritic Cells Are Affected In Vivo in Hepatitis C Virus-Infected PatientsToll-Like Receptors and Viruses: Induction of Innate Antiviral Immune ResponsesTrypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccineVaccine platforms combining circumsporozoite protein and potent immune modulators, rEA or EAT-2, paradoxically result in opposing immune responsesDirected antigen targeting in vivo identifies a role for CD103+ dendritic cells in both tolerogenic and immunogenic T-cell responsesRapid maturation of effector T cells in tumors, but not lymphoid organs, during tumor regression.Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma.Direct TLR2 signaling is critical for NK cell activation and function in response to vaccinia viral infection.Targeting a mimotope vaccine to activating Fcgamma receptors empowers dendritic cells to prime specific CD8+ T cell responses in tumor-bearing mice.Inhibition of TLR4 signaling prolongs Treg-dependent murine islet allograft survival.Toll-like receptor mediated regulation of breast cancer: a case of mixed blessings.Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity.Immune tolerance induction to factor IX through B cell gene transfer: TLR9 signaling delineates between tolerogenic and immunogenic B cells.Ubiquitous points of control over regulatory T cells.Oral vaccination with attenuated Salmonella enterica strains encoding T-cell epitopes from tumor antigen NY-ESO-1 induces specific cytotoxic T-lymphocyte responses.CD8+ T-cell dysfunction due to cytolytic granule deficiency in persistent Friend retrovirus infection.Toll-like receptor agonists in cancer therapy.Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis.Targeting the TLR9-MyD88 pathway in the regulation of adaptive immune responses.CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.Innate signals compensate for the absence of PKC-{theta} during in vivo CD8(+) T cell effector and memory responsesAn alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancerVaccines and immunotherapeutics for the treatment of malignant diseaseSOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling.Toll-like receptor 2 controls expansion and function of regulatory T cellsTumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells.NKG2D is required for NK cell activation and function in response to E1-deleted adenovirusInducible heat shock protein 70 expression as a potential predictive marker of metastasis in breast tumors.CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells.Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent.Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cellsModular injectable matrices based on alginate solution/microsphere mixtures that gel in situ and co-deliver immunomodulatory factors.Intrinsic IL-21 signaling is critical for CD8 T cell survival and memory formation in response to vaccinia viral infection.In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines.A novel TLR3 inhibitor encoded by African swine fever virus (ASFV).CD8+ T-cell memory in tumor immunology and immunotherapy.Tc17 CD8 T cells: functional plasticity and subset diversity.Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells
P2860
Q26785545-E2336CE6-FB57-4D56-BDB7-C2D166E542BFQ27008946-3F8C11DC-C914-4FC5-B33B-329AE0807EB3Q27480367-756B67AC-AEFD-4D85-A50E-D193A1099890Q27487393-0698CE67-FB58-4D81-815C-3D82B76C892EQ28483146-F2735457-951F-4D34-87AB-6AE368D5CE40Q28740832-E8A6E9ED-81D9-4550-9174-14ECF22D0757Q30505427-3AACCF3B-7FBF-451C-8024-A884DC75FD47Q33296983-594DD757-9B73-4C39-96D1-9C123481020DQ33509292-30F077DA-6CE4-4B29-AD4D-5E01EF3D9599Q33543131-F83E6706-4278-483D-9185-1DD655D9C501Q33584637-17C61251-43E6-44A2-BF5C-B4670BBBABA1Q33598788-E6CDCACF-BA19-4F0E-906A-197B3B56030FQ33658124-837C346D-D9ED-4097-9EC6-7B196EC6B191Q33713903-A0D2E016-ED2A-4577-96CB-B8575B29DB18Q33724236-EE14E597-6B82-4F44-A445-2949B510A04BQ33850593-101E3372-1B0C-4A06-9910-FF782ABCC7E1Q33909195-E4A2D07C-1742-451A-A394-7E5FD52F1729Q33911819-B4D8A4C2-879A-44E9-BA26-09ED34E13948Q33918509-876DFC9D-1ED0-4982-92C6-590E793F595DQ33979892-DFCA1CC3-8AD7-4B52-9483-B0FF3BAE927DQ34048648-3CE2686C-FC46-4309-8127-7BE6121D982DQ34063120-404C277A-20FA-409C-8994-B6AFD7158E26Q34063599-DCAA3248-AA49-4C63-89AB-03692AD44B02Q34090155-6112D54F-757F-422A-BCDD-CC53F5DB2A97Q34170074-EDBE9EE0-9836-42BA-9850-6CF7C843866EQ34211024-3C27047E-F69E-4362-92A6-20D74E1C05E7Q34264024-DAEF0DF3-B6DF-4885-B9A5-CAD630BB4DEBQ34312635-2D22DF18-2FD2-4B27-BF36-13BEEE4D9D6DQ34432661-38BF29D1-F09A-4C02-AA0B-413FDA644082Q34451153-5886D881-45DC-441C-89B7-61B0E175A3D3Q34476278-5CF8B198-DC57-4582-A510-09000B594DBEQ34505881-7D772F10-BA04-4252-8DA6-0CC5915662D6Q34578170-BFD8E124-4639-4C5D-9ECF-D60B801EDD42Q34588908-D6B7C416-53D1-468B-9F0C-82D0A3AA722FQ34688226-3ACF1F7D-DA3D-4E74-8669-5A9BC2503520Q34691545-014C419F-B913-4DDC-862E-EA16355241C7Q34733934-0961522C-258E-4A52-881E-40E8A5C6CEAFQ34768139-72877252-D0D9-4F4C-B3BF-203DD8995D94Q34856750-45F74A8C-507E-431D-9FF7-2BE9842ED7F9Q34856800-5344529C-1F9D-4856-A563-1AE528ADF078
P2860
Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Persistent Toll-like receptor ...... T cell-mediated CD8 tolerance.
@en
Persistent Toll-like receptor ...... T cell-mediated CD8 tolerance.
@nl
type
label
Persistent Toll-like receptor ...... T cell-mediated CD8 tolerance.
@en
Persistent Toll-like receptor ...... T cell-mediated CD8 tolerance.
@nl
prefLabel
Persistent Toll-like receptor ...... T cell-mediated CD8 tolerance.
@en
Persistent Toll-like receptor ...... T cell-mediated CD8 tolerance.
@nl
P2093
P2860
P356
P1433
P1476
Persistent Toll-like receptor ...... T cell-mediated CD8 tolerance.
@en
P2093
Ching-Tai Huang
Drew M Pardoll
Xiaopei Huang
Yiping Yang
P2860
P304
P356
10.1038/NI1059
P407
P577
2004-04-04T00:00:00Z